Dagoberto Cid- Guerrero¹*, Araujo-Conejo² and Gloria G Guerrero Arturo³

¹Hospital General Zacatecas "Luz Gonza'lez Cosi'o" de los Servicios Pu'blicos de Salud IMSS Bienestar, México
²Hospital General de Zacatecas, Departamento de Investigación de los Servicios de Salud (SSZ), “IMSS Bienestar” Zacatecas, Zac, México
³Unidad Académica de Ciencias Biológicas, Universidad Autónoma de Zacatecas “Francisco García Salinas”, Zacatecas, Zac, México

*Corresponding Author: Dagoberto Cid- Guerrero, Hospital General Zacatecas "Luz Gonza'lez Cosi'o" de los Servicios Pu'blicos de Salud IMSS Bienestar, México. cidgrod@yahoo.com.mx

Received: November 26, 2024; Published: December 27, 2024

Abstract

The activation of the immune response to antigens is initiated by the molecular recognition of pattern associated to pathogens and pattern of recognition receptor son antigen presenting cells (macrophages and dendritic cells (PRRs), leading to antigen processing and peptide presentation to T lymphocytes through the interaction of MHC I/II to TCR receptor. The overcome of the induction of the immune response is the lymphocyte proliferation, differentiation of T and B cells for cytokines and antibodies production. Importantly the expression of costimulatory molecules as CD80/CD86, CTAL-4, CD28. CD40/CD40L. Interestingly, ABATACEPT chimeric protein formed by the extracellular domain of the antigen 4 associated to cytotoxic lymphocytes T and a fragment of the Fc portion of the Immunoglobulins constant region, resulting in a modulation of the activation of the B and T cellular immune response, and thus, inhibition of inflammation, and therefor in an amelioration of the physical function of the patients with arthritis rheumatoid Therefore, in based on this, herein it is analyzed the potential of Abatacept, a commercial drug (Ohrencia from Bristol-Myers Squibb), as a modulator of the immune response against SARS-CoV2.

 Keywords: Abatacept; COVID-19; SARS.CoV2; innate and adaptive immune response; costimulatory molecules. B and T cell llymphocytes

References

1. World Health Organization. “Naming the coronavirus disease (COVID-19) and the virus that causes it” (2020).
2. Berlin D., et al. “Severe COVID-19”. The New England Journal of Medicine 383 (2020): 2451-2460.
3. Chaomin W., et al. “Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China”. JAMA Internal Medicine 180 (2020): 934-943.
4. Varga Z., et al. “Endothelial cell infection and endotheliitis in COVID-19”. The Lancet 395 (2020): 1417-1418.
5. Zhang Y., et al. “Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19”. The New England Journal of Medicine 382 (2020): e38.
6. Ma L., et al. “Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications”. Cardiothoracic and Vascular Anesthesia 35 (2021): 1860-1865.
7. Carsana l., et al. “Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy”. (2020).
8. Henderson L., et al. “On the Alert for Cytokine Storm: Immunopathology in COVID-19”. Arthritis and Rheumatology 72 (2020): 1059-1063.
9. Suntharalingam G., et al. “Cytokine Storm in a Phase 1 Trial of the anti-CD28 Monoclonal Antibody TGN1412”. The New England Journal of Medicine 355 (2006): 1018-1028.
10. Tan L., et al. “Lymphopenia predicts disease severety of COVID-19: a descriptive and predictive study”. Signal Transduction and Targeted Therapy 5 (2020): 33.
11. García A., et al. “Cytokine release syndrome. Reviewing a new entity in the intensive care unit”. Medicina Intensiva 43 (2019): 480-88.
12. Linsley P., et al. “The clinical utility of inhibiting CD28-mediated co estimulation”. Immunology Review 229 (2009): 307-321.
13. Bayry J. “Autoimmunity: CTLA-4: a key protein in autoimmunity”. Nature Reviews Rheumatology 5 (2009): 244-245.
14. Genovese MC., et al. “Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition”. The New England Journal of Medicine 353 (2005): 1114–1123.
15. Liu P., et al. “Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86 and pro-inflammatory cytokine expression in human B cells”. Arthritis Research Therapy 22 (2020): 64.
16. Aamir S., et al. “Insights into the structure, Replication, and Pathogenesis of the severe acute respiratory syndrome Coronavirus 2”. ReGEN Open (2022): 2.
17. Bramanete CT., et al. “Randomized trial of Metformin, Ivermectin,, and Fluvoxamine for Covid-19”. The New England Journal of Medicine 387 (2022): 599-610.
18. Fehr AR., Perlman S. Coronaviruses: An Overview of their replication and pathogenesis”. In Coronaviruses. Berlin: Springer (2022): 1-23.
19. Mossel EC., et al. “SARS-CoV replicates in primary human alveolar type II cell cultures infected with severe acute respiratory syndrome coronavirus”. Virology 372 (2008): 127-135.
20. Qian Z., et al. “Innate Immune response of human alveolar type II cells infected with severe acute respiratory syndrome coronavirus”. American Journal of Respiratory Cell and Molecular Biology 48 (2013): 742-748.
21. Rothan HA and Byrareddy SN. “The epidemiology and pathogenesiis of coronavirus disease (COVID-19) outbreak”. Journal of Autoimmune 109 (2020): 102433-102433.
22. Hussain A., et al. “Novel COVID-19; A comprehensive review of transmission, manifestation, and pathogenesis”. Cureus 12 (2020): e8184-e8184.
23. Chen Y., et al. “Emerging coronaviruses: Genome structure, replicatoin, and pathogenesis”. Journal of Medical Virology 92 (2020): 418-423.
24. Chen Y and Guo D. “Molecular mechanism of coronavirus RNA capping and methylation”. Virology Sin 31 (2016): 3-11.
25. Ge X-Y., et al. “Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor”. Nature 503 (2013): 535-538.
26. Zhu N., et al. “Novel Coronavirus Investigatin and Research Team. A novel coronavirus from patients with pneumonia in China”. The New England Journal of Medicine 382 (2020): 727-733.
27. Malik YA. “Properties of coronavirus and SARS-CoV2”. Malaysian Journal of Pathology 42 (2020): 3-11.
28. Mehta P., et al. “HLH Across Speciality Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression”. Lancet (London, England) 395 (2020): 1033-1034.
29. Zhang J., et al. “Progress and prospects on vaccine development against SARS-CoV-2”. Vaccines (2020): 153.
30. O’Brien MP., et al. “Subcutaneous REGEN-COV antibody combination to prevent Covid-19”. The New England Journal of Medicine 385 (2021): 1184-1195.
31. Jayk Bernal A., et al. “Molnupiravir for oral treatment of Covid 19 in nonhospitalized patients”. The New England Journal of Medicine 386 (2022): 509-520.
32. Nakashima K., et al. “Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase- dependent and –independent pathways”. Microbiology Immunology 55 (2011): 774-782.
33. Schaller MA., et al. “Ex vivo SARS-CoV2 infection of human lung reveals heterogenous host defense and therapeutic responses”. Insight 6 (2021): e148003.
34. Postler TS., et al. “Metformin selectively dampens the acute inflammatory response through an AMPK-dependent mechanism”. Scientific Report 11 (2021): 18721.
35. Xin G., et al. “Metformin uniquely prevents thrombosis by inhibiting platelet activation and mtDNA release. Scientific Report 6 (2016): 36222.
36. Xian H., et al. “Merformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRPL3 inflammasome activation and pulmonary inflammation”. Immunity 54 (2021): 1463: e11-1477.e11.
37. Bramante CT., et al. “Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity”. Journal of Medical Virology 93 (2021): 4273-4279.
38. Gordon DE., et al. “A SARS-CoV-2 protein interaction map reveals targets for drug repurposing”. Nature 583 (2020): 459-468.
39. Del Campo JA., et al. “Simvastatin and metformin inhibit cell growth in hepatitis C”. PLoS One 13 (2018): e0191805.
40. Popp M., et al. “Ivermectin for preventing and treating COVID-19”. Cochrane Database System Review 7 (2021): CD015017.
41. López-Medina E., et al. “Effect of invermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial”. JAMA 325 (2021): 1426-1435.
42. Facente SN., Reiersen AM., Lenze EJ., Boulware DR., Klausner JD., Fluvoxamine for the early treatment of SARS-CoV2 infection: a review of current evidence”. Drugs 81 (2021): 2081-2089.
43. Reis G., et al. “TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized, platform clinical trial”. Lancet Global Health 10 (2022): e42-e51.
44. Lee TC., et al. “Fluvoxamine for outpatients’ management of COVID- 19 to prevent hospitalization: a systematic review and meta-analysis”. JAMA Network Open 5 (2022): e226269.
45. Lenze EJ., et al. “Fluvoxamine vs Placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial”. JAMA 324 (2020): 2292-22300.
46. Seftel D and Boulware DR. “Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19”. Open Forum Infectious Diseases 8 (2021): ofab050.
47. Boulware DR., et al. “A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19”. The New England Journal of Medicine 383 (2020): 517-525.

Citation

Citation: Dagoberto Cid- Guerrero., et al. “ABATACEPT as a Modulator of the T and B Cellular Immune Response Against Severe COVID 19".Acta Scientific Medical Sciences 9.1 (2025): 115-122.

Copyright

Copyright: © 2025 Dagoberto Cid- Guerrero., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.